alexa
Reach Us +1(850)754-6199
Malaria And Matrix Metalloproteinases: New Perspectives For Adjuvant Therapy | 4852
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Malaria and matrix metalloproteinases: New perspectives for adjuvant therapy

3rd World Congress on Biotechnology

Mauro Prato

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.009

Abstract
Besides primary therapy including quinine and artesunate, effective against Plasmodium parasite, several new adjunctive therapies to reduce clinical symptoms and mortality of severe malaria have undergone recent trials. However, results have been disappointing, with albumin being so far the only promising adjuvant therapy. Thus, research for new targets aimed at defining new affordable treatment appears urgent. Recently, convincing evidence on the involvement of human Matrix Metalloproteinases (MMP) in malaria pathogenesis emerged. In vivo, enhanced mRNA/protein levels of a large kaleidoscope of MMP, including MMP-1, -2, -7, and -9, were described in human or murine models of cerebral malaria (CM). In vitro, a tight relationship between human MMP-9 and haemozoin (HZ, malarial pigment), a Plasmodium parasite product resulting from haemoglobin digestion, was demonstrated by my group. In human monocytes and endothelium, HZ enhanced expression, release and activity of MMP-9 and several MMP-9-related molecules, including cytokines (TNFalpha, IL-1beta), chemokines (MIP-1alpha, IL-8), and enzymes/inhibitors from gelatinase granules (lysozyme, tissue inhibitors of metalloproteinases/TIMP). Enhancement of MMP-9 and related molecules appeared dependent on HZ lipid moiety, and a major role for 15-hydroxyeicosatetraenoic acid (15-HETE), a HZ lipoperoxidation derivative, was suggested. Additionally, p38MAPK and NF-kappaB signalling activation was required. Since MMP play a major role disrupting endothelial tight junctions and sub-endothelial basement membrane, along with modulating pro-inflammatory activity, they could be crucial for eliciting blood-brain barrier permeability and inflammation during CM. Therefore, further studies on MMP involvement in malaria will help to clarify mechanisms underlying severe malaria etiopathogenesis, in order to design new targeted adjuvant therapies.
Biography
Mauro Prato graduated in Medical Biotechnology in 2001 and completed his PhD in Biochemistry and Cellular Biotechnology in 2005 at the University of Torino, Italy, where he has been working as an Adjunct Professor of Biochemistry since 2008. His main research interests cover the investigation of the involvement of human matrix metalloproteinases in malaria, a new research field that he successfully pioneered. He has published 19 papers in peer-reviewed journals, 3 chapters in international books and more than 40 communications in well-established conferences. He is serving as an editorial board member of the Journal of Bacteriology and Parasitology (OMICS Group).
Top